8-K: Recursion Pharmaceuticals Reports Q1 2025 Financial Results and Provides Business Update, Streamlining Pipeline and Extending Cash Runway

Recursion Pharmaceuticals announced its Q1 2025 financial results, highlighting pipeline advancements, partnership achievements, and operational streamlining, extending its cash runway into mid-2027.

Summary

• Recursion Pharmaceuticals reported its Q1 2025 financial results, showcasing progress in its pipeline and partnerships.
• The company achieved a fourth milestone in its Sanofi collaboration, generating $7 million, and has received a total of $130 million from the partnership to date.
• Recursion is streamlining its portfolio, focusing on oncology and rare diseases, and has deprioritized three clinical programs and one preclinical program.
• Preliminary data from the Phase 1b/2 TUPELO study of REC-4881 in familial adenomatous polyposis (FAP) showed a median 43% reduction in polyp burden in a small group of patients.
• The company's cash and cash equivalents were $509 million as of March 31, 2025.
• Total revenue for Q1 2025 was $15 million, compared to $14 million in Q1 2024.
• Research and development expenses increased to $130 million, driven by the Tempus agreement and the Exscientia business combination.
• The net loss for Q1 2025 was $202.5 million, compared to $91.4 million in Q1 2024.
• Recursion expects a cash burn of equal to or less than $450 million for 2025, excluding partnering or financing inflows, and projects a cash runway into mid-2027.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is streamlining operations and has a solid cash runway, the increased net loss and discontinuation of some programs temper the positive aspects.

Positives

• The Sanofi collaboration continues to be fruitful, with a $7 million milestone achieved and potential for further payments.
• Early data for REC-4881 in FAP patients shows promising reductions in polyp burden.
• Preclinical data for REC-7735 indicates potential as a highly selective PI3K H1047R inhibitor.
• The company is streamlining operations and prioritizing high-potential programs.
• Recursion has a strong cash position with a runway into mid-2027.
• The company is integrating data from Tempus and HealthVerity to enhance its platform and clinical development.

Negatives

• The company is discontinuing development of several clinical programs, indicating setbacks in those areas.
• The net loss for Q1 2025 increased significantly compared to Q1 2024.
• Research and development expenses have increased substantially.
• The company is experiencing a significant cash burn.

Risks

• The success of clinical programs is subject to inherent risks and uncertainties.
• The company's ability to leverage and enhance its drug discovery platform is crucial for future success.
• Obtaining regulatory approval for drug candidates is not guaranteed.
• The company faces risks related to cyberattacks and disruptions to its technology systems.
• Macroeconomic issues, such as inflation, could impact the business.

Future Outlook

Recursion anticipates continued progress in its pipeline programs, driven by its Recursion OS platform, and expects to achieve key milestones in the near term. The company projects a cash runway into mid-2027 and aims to transform drug discovery and development through AI and automation.

Management Comments

• 'Our decade-long investment in AI is driving a decisive, data-led portfolio strategy,' said Chris Gibson, Co-Founder and CEO of Recursion.
• 'We are prioritizing high-potential programs to accelerate better treatments to patients, building on our platform's unique ability to learn and lead this transformative shift in drug discovery.'
• 'Our portfolio evolution reflects Recursions commitment to advancing medicines in areas of high unmet need where we believe we can have the greatest impact,' said Najat Khan, Chief R&D Officer and Chief Commercial Officer at Recursion.
• 'As part of our business combination with Exscientia, we are proactively streamlining our portfolio, platform, and operations, making deliberate tradeoffs to focus resources on programs with the strongest scientific rationale and the highest potential for nearand long-term impact.'
• 'Recursion is stronger as a combined company, allowing us to not only deliver on operational goals more efficiently, but also be nimble in periods of uncertainty,' stated Ben Taylor, CFO of Recursion and President Recursion UK.
• 'We have been able to significantly lower costs without cutting important platform capabilities by decreasing overall capacity.'

Industry Context

Recursion's focus on TechBio and leveraging AI for drug discovery aligns with the growing trend of integrating technology and biology to accelerate drug development. The company's partnerships with major pharmaceutical companies like Sanofi and Roche demonstrate the industry's interest in AI-driven drug discovery platforms.

Comparison to Industry Standards

• Recursion's approach to drug discovery, leveraging AI and high-throughput screening, aims to reduce the time and cost associated with traditional methods.
• The company's partnerships with Roche and Genentech are similar to other collaborations in the industry, such as the partnership between Exscientia and Sanofi, which also focuses on AI-driven drug discovery.
• Recursion's focus on streamlining its pipeline and prioritizing high-potential programs is a common strategy in the pharmaceutical industry to optimize resource allocation and improve efficiency.
• The reported 43% median reduction in polyp burden in FAP patients treated with REC-4881 is a promising result, but further data is needed to compare it to existing treatments or other investigational therapies.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the increased net loss and discontinued programs.
• Employees may be affected by the streamlining of operations and potential job losses.
• Patients may benefit from the company's focus on high-potential programs and the development of new therapies.
• Partners may see increased value from the company's streamlined operations and focus on key collaborations.

Next Steps

• Initiate CDK7 combination studies in 1H25.
• Release additional data in FAP from TUPELO in 2H25.
• Nominate a development candidate for PI3K H1047R in 2H25.
• Release early Phase 1 safety and PK monotherapy data for RBM39 in 1H26.
• Release early Phase 1 safety and PK monotherapy data for MALT1 in 2H26.
• Initiate Phase 1 for ENPP1 in 2H26.

Key Dates

Keywords

Recursion Pharmaceuticals, Financial Results, Pipeline Update, Partnerships, TechBio, Oncology, Rare Disease, REC-4881, REC-7735, Cash Runway